Displaying 76 (all) recruiting clinical trials.
-
Site for CHRONIC VENOUS THROMBOSIS: RELIEF WITH ADJUNCTIVE CATHETER-DIRECTED THERAPY
To determine if EVT should be routinely used to treat DIO-PTS, we plan to perform a multicenter randomized clinical trial (the Chronic Venous Thrombosis: Relief ...Phase
Interventional
-
Zenith p-Branch Pivotal Study
This clinical investigation is intended to evaluate the safety and effectiveness of the Zenith® p-Branch™ in combination with Atrium iCAST™ covered stents for the treatment ...Phase
Interventional
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The optimal treatment for children and adolescents with Ph+ ALL has not yet been determined. There is now a general consensus among the North American ...Phase
Interventional
-
Site for WUH: COG# AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Site for ?Despite recent improvements in outcome for children with newly diagnosed high-risk neuroblastoma, cure rates remain unsatisfactory. Further, these gains have been the result ...Phase
Interventional
-
Site for WUH: AGCT1532: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Site for To determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is superior to standard BEP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs.Phase
Interventional
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Site for Low-grade gliomas (LGG) are the most common central nervous system tumor among children, accounting for approximately one-third of pediatric brain tumors. These tumors ...Phase
Interventional
-
Site for ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Site for This trial studies how well selumetinib works in treating patients with low-grade glioma. Selumetinib is a drug that works by blocking a protein ...Phase
Interventional
-
Site for DV0004 A MULTICENTER RANDOMIZED OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF THE PREFILLED SAFETY SYRINGE OR AUTO-INJECTOR FOR THE SUBCUTANEOUS SELF-INJECTION OF BIMEKIZUMAB SOLUTION BY SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
Site for DV0004 is a Phase 3, multicenter, open-label, randomized, noncomparator, North America and Europe substudy to PA0012 in adult subjects with active psoriatic arthritis ...Phase
Interventional
-
A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
This is a Phase 3, randomized, placebo-controlled, parallel-group, multi-site, double-blind (with in-house blinding) study of pembrolizumab + CRT versus placebo + CRT in participants with MIBC (T2-T4aN0M0 ...Phase
Interventional
-
Site for A Multicenter Randomized Double-Blind Parallel Group Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure
Site for This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (LVEF =40%) who have ...Phase
Interventional
